Masimo’s (MASI) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Masimo (NASDAQ:MASI) in a report published on Wednesday morning,Benzinga reports. BTIG Research currently has a $198.00 target price on the medical equipment provider’s stock.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Piper Sandler lifted their price objective on Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 6th. Finally, Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 24th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $194.00.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $143.16 on Wednesday. Masimo has a 52 week low of $133.70 and a 52 week high of $194.88. The company has a 50-day moving average price of $145.03 and a 200 day moving average price of $153.85. The company has a market cap of $7.69 billion, a P/E ratio of -16.80 and a beta of 1.28. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The business had revenue of $617.00 million for the quarter. Research analysts predict that Masimo will post 4.1 earnings per share for the current year.

Insider Transactions at Masimo

In other news, Director William R. Jellison acquired 3,000 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were bought at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the purchase, the director directly owned 4,790 shares of the company’s stock, valued at approximately $699,244.20. This trade represents a 167.60% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 9.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Masimo

Large investors have recently added to or reduced their stakes in the company. Twin Tree Management LP acquired a new position in Masimo in the 1st quarter worth $29,000. MAI Capital Management increased its position in shares of Masimo by 176.7% during the second quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 129 shares during the last quarter. Hilltop National Bank acquired a new position in shares of Masimo in the second quarter worth about $37,000. Anderson Financial Strategies LLC purchased a new position in Masimo in the first quarter valued at about $49,000. Finally, Smartleaf Asset Management LLC grew its stake in Masimo by 80.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 136 shares in the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.